WASHINGTON – At this week's annual meeting of the American Association for Cancer Research, a number of similarities emerged among labs offering cancer gene panels on next-gen sequencing platforms. For example, several groups that offer such services reported that lung cancer is the most common tumor type they see, followed by breast cancer and colorectal cancer. Likewise, these labs all see the same top three mutated genes: TP53, PI3K, and KRAS.
At AACR, Early Providers of NGS-based Cancer Panels Debate 'Actionable' Mutations, Regulatory Issues
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.